

A
EXTRA
INTRA
SP SEMA PSI IPT 1-4 TM JM KD CT
W.T. MET
N
C
α-chain
β-chain
SP ND K 1-4 PLD
W.T. HGF
SP SEMA PSI IPT 1-4 E H
DECOY MET
SEMA-PSI
SEMA
PSI-IPT
IPT
SP ND K 1-4 PLD E H
HGF
UNCL. HGF
R494Q
HGF-α
HGF NK1
HGF-β
B
BSA (ng)
SEMA
SEMA-PSI
DECOY MET
MW
125
250
500
1000
2000
kDa
206
115
98
55
38
29
PSI-IPT
IPT
HGF-α
UNCL. HGF
HGF
HGF NK1
HGF-β
250
150
75
50
37
25
20
15
10

Figure 1



A
Active HGF binding
OD 450 nm
HGF (nM)
Decoy Met
Sema-PSI
Sema
PSI-IPT
IPT
BSA
B
Decoy Met binding
Factor conc. (nM)
C
Sema-PSI binding
Factor conc. (nM)
Active HGF
Pro-HGF
HGF-α
HGF NK1
D
IPT binding
Factor conc. (nM)

Figure 2



A
Deleted IPT forms
SP IPT 1-4 E H
IPT N C
IPT Δ1 N C
IPT Δ1-2 N C
IPT 4 N C
IPT 3 N C
B
Deleted IPT binding
OD 450 nm
2000
1750
1500
1250
1000
750
500
250
0
0.0 2.5 5.0 7.5 10.0 12.5
HGF-α (nM)
IPT
IPTΔ1
IPTΔ1-2
IPT-4
IPT-3
BSA

Figure 3



A
N
SEMA
PSI
IPT 1-4
N
JM
KD
CT
C
C
W.T. Met
Met Δ 25-741
B
W.T. A549
W.T. MDA
TOV Met Δ 25-741
TOV Empty V.
W.T. TOV
kDa
160
105
75
IP α-Met, WB SA
p170 Met
p145 Met
Met Δ25-741
160
105
75
IP α-Met, WB α-Met
C
Met Δ 25-741
W.T. TOV
HGF + - + -
kDa
195
117
97
50
HGF-Met Δ25-741
IP anti-Met WB anti-HGF
D
Control
1% FBS
Active HGF
Pro-HGF
HGF NK1
NK1-NK1
kDa
199
116
94
54
37
Met Δ25-741
Ig
IP anti-Met WB anti-pTyr
IP anti-Met WB anti-Met
E
ND
K1
ND
K1
SP
N
H
C
NK1-NK1

Figure 4



A
Empty V.
Sema-PSI
IPT
Decoy Met
Empty V.
Sema-PSI
IPT
Decoy Met
HGF →
p170 Met →
p145 Met →
IP anti-Met, WB anti-pTyr
p170 Met →
p145 Met →
IP anti-Met, WB anti-Met
B
Branching morphogenesis assay
No. of tubules/spheroid
25
20
15
10
5
0
– HGF
+ HGF
**
**
**
EV
DM
SP
IPT
C
Empty
Empty + HGF
Decoy Met
Decoy Met + HGF
Sema-PSI
Sema-PSI + HGF
IPT
IPT + HGF

Figure 5



A
Tumor latency
% tumor-free animals
Time (days)
Empty v.
Decoy Met
SEMA-PSI
IPT
B
Tumor burden
Tumor volume (mm³)
Time (days)
Empty v
Decoy Met
SEMA-PSI
IPT
C
Transgene expression
Empty vector
Sema-PSI
Decoy Met
IPT
D
Tumor vessel analysis
Vessel density (vessel/mm²)
EV
DM
SP
IPT
E
Metastasis incidence (%)
EV 4/6
SP 1/6
IPT 1/6
DM 0/6
mc
vs
F
vs
mc

Figure 6